NCT04060394 - Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 13, 2019

Primary Completion Date

December 27, 2023

Study Completion Date

March 30, 2024

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG

Phase I and Phase II: LAE001/prednisone + afuresertib

In the Phase I portion of the study will identify the RPD2 of the combined therapy. In the Phase II will evaluate LAE001/prednisone + afuresertib at the RP2D (Cohort 1) and docetaxel/prednisone + afuresertib (Cohort 2).

Trial Locations (17)

10408

National Cancer Center, Goyang-si

13215

Associated Medical Professionals of NY, Syracuse

13605

Seoul National University Bundang Hospital, Seongnam-si

29605

Greenville Hospital System, Greenville

31901

Piedmont Columbus Regional Research Institute, Columbus

60637

University of Chicago, Chicago

66606

Cotton-O'Neil Clinical Research Center, Topeka

75251

Mary Crowley Cancer Research Centers, Dallas

76508

Baylor Scott and White Health, Temple

85741

Urological Associates of Southern Arizona, Tucson

92024

California Cancer Associates for Researh & Excellence, Inc, Encinitas

97439

Oregon Urology Institute, Florence

98405

Northwest Medical Specialties, PLLC, Tacoma

06360

Eastern Connnecticut Hematology/Oncology Associates, Norwich

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Seoul

05505

Asan Medical Center, Seoul

All Listed Sponsors

lead

Laekna Limited

INDUSTRY